Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving Average - Here's Why

Key Points

• Seres Therapeutics (MCRB) stock fell below its 50-day moving average of $11.38, trading as low as $8.11 and last at $8.28 on volume of 37,720 shares (down about 4.5%).
• Analysts are mixed — one Buy, one Hold and one Sell — leaving a consensus rating of Hold with an average price target of $14; recent notes include a sell from Weiss Ratings, Wall Street Zen cutting to sell, and Canaccord keeping a $22 buy target.
• Fundamentals: market cap ~$79.4M and P/E 12.55; the company reported Q1 EPS of ($1.89) which beat estimates by $0.50 on $0.44M revenue, and roughly 59% of shares are held by institutions.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.38 and traded as low as $8.11. Seres Therapeutics shares last traded at $8.28, with a volume of 37,720 shares.

Analysts Set New Price Targets

MCRB has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Seres Therapeutics in a report on Monday, December 29th. Wall Street Zen cut Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 14th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research note on Friday, March 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $14.00.

Seres Therapeutics Stock Down 4.5%

The firm has a market capitalization of $79.41 million, a P/E ratio of 12.55 and a beta of 0.31. The business's 50 day moving average is $11.38 and its 200-day moving average is $15.25.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($1.89) earnings per share for the quarter, topping the consensus estimate of ($2.39) by $0.50. The business had revenue of $0.44 million for the quarter. Research analysts forecast that Seres Therapeutics, Inc. will post -0.38 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Seres Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company's stock valued at $1,282,000 after acquiring an additional 1,160 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company's stock worth $214,000 after acquiring an additional 3,918 shares during the last quarter. State Street Corp lifted its holdings in shares of Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company's stock worth $504,000 after acquiring an additional 4,170 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Seres Therapeutics by 4.8% in the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company's stock valued at $1,536,000 after purchasing an additional 4,723 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock valued at $103,000 after purchasing an additional 5,157 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.